Daily CCL5 neutralization decreased the number of ZIKV-infected hBMECs by only 20%, while neutralizing antibodies to CCR3/CCR5 receptors reduced ZIKV infection by 50% compared to controls (Fig. 2B). The gene discussed is CCL5; the disease is Zika virus infectious disease.